Journals / Turkish Journal of Hematology / 2010 / Cilt: 27 - Sayı: 3

Çocukluk çağında immun trombositopenik purpura ve farklı klinik seyir: Tek merkezin 16 yıllık deneyimi

Variant clinical courses in children with immune thrombocytopenic purpura: Sixteen year experience of a single medical center

Pages
147–155
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: It is concluded that ITP in childhood is a common disease with low morbidity and mortality.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Immune thrombocytopenic purpura (ITP) is the most common cause of acquired thrombocytopenia in children.
📊
Key Findings & Data:The objective of this study was to evaluate the presenting features, variation in the clinical courses, initial response rate to therapy, and long-term outcome in patients with ITP.
💡
Conclusion & Impact:Conclusion: It is concluded that ITP in childhood is a common disease with low morbidity and mortality.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Immune thrombocytopenic purpura (ITP) is the most common cause of acquired thrombocytopenia in children. The objective of this study was to evaluate the presenting features, variation in the clinical courses, initial response rate to therapy, and long-term outcome in patients with ITP. Materials and Methods: Three hundred and fifty out of 491 newly diagnosed patients with ITP between the initial diagnosis ages of 6 months to 16 years were included in this retrospective, descriptive study. Patients with acute vs chronic ITP, acute vs recurrent ITP and chronic vs recurrent ITP were compared in terms of age at diagnosis, gender, initial platelet count, response rate to initial therapy, long-term outcome, and total duration of follow-up. Results: The clinical courses of the patients were determined as acute, chronic and recurrent in 63.8%, 29.1%, and 7.1%, respectively. Platelet count >20x109/L and initial diagnosis age >10 years were found to increase the probability of chronic outcome by at least two-fold. Conclusion: It is concluded that ITP in childhood is a common disease with low morbidity and mortality. In addition to the acute and chronic form, a rare recurrent form, which accounts for about 4-7% of all ITP patients, should be considered.

Özet

Amaç: İmmun trombositopenik purpura (ITP) çocukluk çağında en sık görülen edinsel trombositopeni nedenlerindendir. Bu çalışmada, ITP’li çocuklarda başvuru bulguları, klinik seyirlerindeki farklılıklar, tedaviye ilk yanıt ve uzun dönem prognozlarının değerlendirilmesi amaçlandı. Yöntem ve Gereçler: Bu retrospektif, tanımlayıcı araştırmaya tanı yaşı 6 ay-16 yıl olan ITP’li 491 hastadan 350’si dahil edildi. Akut, kronik ve rekürren ITP’li olgular tanı yaşı, cinsiyet, başvurudaki trombosit sayısı, ilk tedavi yanıtı, prognoz ve izlem süreleri yönünden ikili gruplar halinde karşılaştırıldı. Bulgular: Hastaların %63.8’i akut, %29.1’i kronik ve %7.1’i rekürren ITP olarak tanımlandı. Trombosit sayısı >20x109/L ve başvuru yaşının >10 yaş olmanın kronik ITP olasılığını 2 kat arttırdığı görüldü. Sonuç: Sonuç olarak ITP, çocukluk yaş grubunda mortalite ve morbiditesi düşük bir hastalıktır. Akut ve kronik seyirli ITP dışında, tüm ITP olgularının %4-7’sini oluşturan rekürren formların da olabileceği akılda tutulmalıdır.

🔖

Cite This Article

YAPRAK, I., ATABAY, B., DURAK, İ., TÜRKER, M., ÖNİZ, H., ÖZER, E. A. (2010). Çocukluk çağında immun trombositopenik purpura ve farklı klinik seyir: Tek merkezin 16 yıllık deneyimi. Turkish Journal of Hematology, Cilt: 27 - Sayı: 3, 147–155. https://ajindex.com/articles/413169

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008
  2. Nugent DJ. Childhood immunothrombocytopenic purpura. Blood Rev 2002;16:27-9
  3. Kühne T. Immune thrombocytopenic purpura in childhood: controversies and solutions. Pediatr Blood Cancer 2006;47(5 Suppl):650-2
  4. Belletrutti M, Ali K, Barnard D, Blanchette V, Chan A, David M, Luke B, Price V, Ritchie B, Wu J; Canadian Pediatric Chronic ITP Working Group; Canadian Pediatric Thrombosis and Hemostasis Network. Chronic immune thrombocytopenic purpura in children: a survey of the Canadian experience. J Pediatr Hematol Oncol 2007;29:95-100
  5. Ozer EA, Yaprak I, Atabay B, Türker M, Akşit S, Sarıoğlu B. Oral cyclic megadose methylprednisolone therapy for chronic immune thrombocytopenic purpura in childhood. Eur J Hematol 2000;64:411-5
  6. Ruggiero A, Annunziata ML, Lazzareschi I, Ridola V, Attinà G, Riccardi R. Chronic immune thrombocytopenic purpura in children: case reports of spontaneous recovery without splenectomy. Pediatr Hematol Oncol 2006;23:471-5
  7. Jayabose S, Levendoglu-Tugal O, Ozkaynkak MF, Visintainer P, Sandoval C. Long-term outcome of chronic immune thrombocytopenic purpura in children. J Pediatr Hematol Oncol 2004;26:724-6
  8. Donato H, Picón A, Martinez M, Rapetti MC, Rosso A, Gomez S, Rossi N, Bacciedoni V, Schvartzman G, Riccheri C, Costa A, Di Santo J. Demographic data, natural history, and prognostic factors of immune thrombocytopenic purpura in children: a multicentered study from Argentina. Pediatr Blood Cancer 2009;52:491-6
  9. Imbach P, Lilleyman JS, Hann IM and Blanchetter, V. S. (eds) (1999) Immune thrombocytopenic purpura. Pediatric Hematology, ed 2 Churchill Livingstone, London: Churchill Livingstone, 1999: 437-53
  10. Jayabose S, Levendoglu-Tugal O, Ozkaynak MF, Sandoval C. Recurrent immune thrombocytopenic purpura in children. Pediatr Hematol Oncol 2006;23:677-82
  11. Walker JH, Walker W. Immune thrombocytopenic purpura in childhood. Arch Dis Child 1961;36:649-57
  12. Kuhne T, Buchanan GR, Zımmerman S. Michaels LA, Kohan R, Berchtold W, Imbach P. A prospective comparative study of 2540 infants and children with newly diagnosed immune thrombocytopenic purpura (ITP) from the intercontinental childhood ITP study group. J Pediatr 2003;143:605-8
  13. Watts RG. Immune thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of Alabama. Clin Pediatr 2004;43:691-702
  14. Imbach P, Kühne T, Müller D, Berchtold W, Zimme